NCT07830758
Resmetirom in Patients With MASH and HFpEF
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Start date changed from estimate of Sep 2026 to Oct 16, 2026
- Notable Recruitment opened
- Trial sites expanded: 0 → 5 locations
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: From first dose through End of Study follow-up (28 days after last dose)
Incidence of treatment-emergent serious adverse events (SAES)
Timeframe: From first dose through End of Study follow-up (28 days after last dose)
Change from baseline in physical examination findings assessed by investigator physical examination
Timeframe: Baseline to Week 24
Change from baseline in body temperature
Timeframe: Baseline to Week 24
Change from baseline resting heart rate
Timeframe: Baseline to Week 24
Change from baseline in respiratory rate
Timeframe: Baseline to Week 24
Change from baseline in seated systolic blood pressure
Timeframe: Baseline to Week 24
Change from baseline in seated diastolic blood pressure
Timeframe: Baseline to Week 24
Change from baseline in PR interval on 12-lead ECG in milliseconds (ms)
Timeframe: Baseline to Week 24
Change from baseline in QRS interval on 12-lead ECG in milliseconds (ms)
Timeframe: Baseline to Week 24
Change from baseline in heart rate on 12-lead ECG in beats per minute (bpm)
Timeframe: Baseline to Week 24
Change from baseline in RR interval on 12-lead ECG in milliseconds (ms)
Timeframe: Baseline to Week 24
Change from baseline in QT interval on 12-lead ECG in milliseconds (ms)
Timeframe: Baseline to Week 24
Change from baseline in QT interval corrected using Bazett's formula (QTcB) in milliseconds (ms)
Timeframe: Baseline to Week 24
Change from baseline in QT interval corrected using Fridericia's formula (QTcF) in milliseconds (ms)
Timeframe: Baseline to Week 24
Number of participants with clinically significant abnormalities in hematology laboratory parameters
Timeframe: Baseline to Week 24
Number of participants with clinically significant abnormalities in blood chemistry laboratory parameters
Timeframe: Baseline to Week 24
Number of participants with clinically significant abnormalities in urinalysis parameters
Timeframe: Baseline to Week 24
Percent change from baseline in liver fat content measured by MRI-Proton Density Fat Fraction (MRI-PDFF)
Timeframe: Baseline to Week 24
Arms and interventions
Arm 1 - ResmetiromExperimental
Participants will receive resmetirom orally once daily for 24 weeks. Resmetirom dose will be based on actual body weight: 80 mg once daily for participants weighing \<100 kg and 100 mg once daily for participants weighing ≥100 kg. Dose reduction by 20 mg will be implemented for concomitant use of a moderate CYP2C8 inhibitor, as specified in the protocol
Arm 2 - Placebo ComparatorPlacebo comparator
Participants will receive matching placebo orally once daily for 24 weeks.
Drugs: Resmetirom, Placebo
Sites
5 sites in 1 country